SMS Lifesciences India Limited (SMSLIFE) Fair Value & Analysis
Healthcare · IN · Market cap ₹3.8B
Fair value as of: Jul 6, 2026
From 24 valuation models · updated today
Share price +10.1% over the past month.
Price vs Fair Value (12 months)
12‑month range ₹1,073 – ₹1,700 · fair‑value band ₹730.34 – ₹1,693 · the ₹1,663 price screens above the ₹1,144 fair value. As of Jul 6, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
SMS Lifesciences India Limited (SMSLIFE) currently trades at ₹1,663, while our model-based Fair Value estimate is ₹1,144 — implying the stock looks roughly 31.2% overvalued today. We read business quality at 65/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
Over the trailing twelve months, SMS Lifesciences India Limited generated revenue of ₹3.3B at a net margin of 5.2%. Revenue declined 10.9% year over year. It earns a return on equity of 9.2%. Net debt stands at ₹835M. Fundamentals as of Jul 6, 2026
Our scenario range runs from ₹730.34 (bear case) to ₹1,693 (bull case); at ₹1,663, the current price sits within that range. The share trades about 6% below its 52-week high and 59% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -27% fair-value upside — at -31%, SMSLIFE screens richer than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 6, 2026. TTM = trailing twelve months.
About the company
SMS Lifesciences India Limited manufactures and sells active pharmaceutical ingredients (APIs) and intermediates in India. The company offers APIs in various therapeutic areas, such as anti ulcer, erectile dysfunction, anti gout, anesthesia, anti infective, anti obesity, antifungal, anti convulsant, anti emetic, ophthalmic, anti worm, and antiemetic. It is also developing APIs in the areas of anti depressant, anti psychotic, anti hypertension, veterinary, antiviral, and anticoagulant. In addition, the company offers intermediates in the anti ulcer, anti migraine, anti hypertension, erectile dysfunction, anti cancer, antifungal, anti obesity, anti emetic, anti depressant, anti worm, anti gout, anti infective, anti convulsant, antiviral, and anesthesia. It also exports its products. SMS Lifesciences India Limited was founded in 1990 and is based in Hyderabad, India.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
SMS Lifesciences India Limited reported revenue of ₹3.4B in FY2025 versus ₹2.6B in FY2021, a compound +6.9%/yr. Reported net income was ₹201M in FY2025, compounding +10.4%/yr from FY2021.
Is SMSLIFE fairly valued? → Check now
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 6, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX34 | R$574.00 | R$357.63 | -38% |
| Regeneron Pharmaceuticals, Inc REGN | $612.50 | $1,280 | +109% |
| UCB SA UCB | €274.90 | €211.40 | -23% |
| argenx SE ARGNF | $900.00 | $382.64 | -57% |
| Samsung Biologics Co 207940 | 1,000,000 KRW | 1,091,384 KRW | +9% |
| CSL Limited CSL | A$116.32 | A$126.60 | +9% |
| Celltrion, Inc 068270 | 171,400 KRW | 74,280 KRW | -57% |
| BioNTech SE B1NT34 | R$29.19 | R$21.38 | -27% |
| Moderna, Inc M1RN34 | R$12.44 | R$5.11 | -59% |
| Innovent Biologics, Inc 1801 | HK$85.35 | HK$21.13 | -75% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is SMS Lifesciences India Limited (SMSLIFE) undervalued?
What is the fair value of SMSLIFE?
What is the quality score of SMSLIFE?
What is the revenue of SMS Lifesciences India Limited (SMSLIFE)?
What is the net profit margin of SMSLIFE?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.